The CMS Sickle Cell Gene Therapy Access Model

IF 24.7 1区医学 Q1 PEDIATRICS

JAMA Pediatrics Pub Date : 2024-12-16 DOI:10.1001/jamapediatrics.2024.5536

Jeromie Ballreich, Ilina C. Odouard, Mariana P. Socal

引用次数: 0

Abstract

This Viewpoint explores and provides policy recommendations for the Cell and Gene Therapy Access Model recently launched by the US Centers for Medicare &amp; Medicaid Services (CMS), which aims to increase access to Medicaid recipiencts with rare and severe diseases.

查看原文本刊更多论文

CMS 镰状细胞基因治疗获取模式

本视点探讨了美国医疗保险和医疗补助服务中心（CMS）最近推出的细胞和基因疗法获取模式，并提出了相关政策建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JAMA Pediatrics PEDIATRICS-

CiteScore

31.60

自引率

1.90%

发文量

357

期刊介绍： JAMA Pediatrics, the oldest continuously published pediatric journal in the US since 1911, is an international peer-reviewed publication and a part of the JAMA Network. Published weekly online and in 12 issues annually, it garners over 8.4 million article views and downloads yearly. All research articles become freely accessible online after 12 months without any author fees, and through the WHO's HINARI program, the online version is accessible to institutions in developing countries. With a focus on advancing the health of infants, children, and adolescents, JAMA Pediatrics serves as a platform for discussing crucial issues and policies in child and adolescent health care. Leveraging the latest technology, it ensures timely access to information for its readers worldwide.